Just how low will Pharma stoop to give their products much needed kudos?
The recent study may give you a valuable insight into how Pharma pulls the strings
On Sunday, 22-Apr-2007, the following study was published:
Benefits of antidepressants for children far outweigh the risks
It goes on to say 'The team found no reported suicides, but 3 percent of those taking the drugs reported suicidal behavior compared with 2 percent of those taking a placebo; the Food and Drug Administration (FDA) researchers had found rates of 4 and 2 percent, respectively.'
'Experts have argued that the warning may well have discouraged doctors from prescribing antidepressants for children and teenagers, and many who would have benefited from such medications have being frightened away.'
Now... where was this study conducted?
Columbus Children's Research Institute
Chief of the Section of Family Practice at Columbus Children’s Hospital, PatrickJ.Fahey,MD,recieved $139,490 funding from GlaxoSmithKline for a 7-month, Multicenter, Parallel, Double-Blind, Placebo-Controlled Comparison of 150-300 mg/day of Extended-Release Bupropion Hydrochloride& Placebo for the Prevention of Seasonal Depressive Episodes in Subjects with aHistory of Seasonal Affective Disorder. He has also recieved funding from Ross Laboratories, $240,640 and from Merck, $63,872.
Call me cynical but what the hell is going on here?
Has it not already been proven that the benefits of antidepressants in children DO NOT outweigh the risks?
This report is scandalous and yet another ploy by Pharma to play down the dangers of SSRi's.
You can read the Columbus Children's Research Institute review here:
Author of The evidence, however, is clear, the Seroxat scandal
Citizens Commission on Human Rights Award Recipient (Twice)